Zoetis Inc. Derivative Asset, Fair Value of Collateral
Zoetis Inc. (ZTS) had Derivative Asset, Fair Value of Collateral of $24.00 million as of 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Notes
us-gaap:DerivativeAssetFairValueOfCollateral · last filed 2021-11-04
- 2021-09-30: Derivative Asset, Fair Value of Collateral $24.00M.
- 2021-06-30: Derivative Asset, Fair Value of Collateral $21.00M.
- 2021-03-31: Derivative Asset, Fair Value of Collateral $30.00M.
- 2020-09-30: Derivative Asset, Fair Value of Collateral $16.00M.
| Period end | Derivative Asset, Fair Value of Collateral |
|---|---|
| 2021-09-30 | $24.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $21.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $30.00M 10-Q · filed 2021-05-06 |
| 2020-09-30 | $16.00M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $25.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $28.00M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |